Company: ARTL
Filing Date: 2025-05-13
Form Type: 10-Q
Source: 0001640334-25-000825
Chunk: 137

Company: ARTELO BIOSCIENCES, INC.
Filing Date: 2025-05-13
Form: 10-Q
Item: Part I, Item 1
Chunk 137
---
  2024  Change Current Assets $1,382  $2,557  $(1,175)Current Liabilities  2,804   1,772   1,032 Working Capital $(1,422) $785  $(2,207)

 21Table of Contents

Our total current assets as of March 31, 2025, were $1.4 million as compared to total current assets of $2.6 million as of December 31, 2024. The decrease in current assets was primarily due to the funding of our operating activities.

Our total current liabilities as of March 31, 2025, were $2.8 million as compared to total current liabilities of $1.8 million as of December 31, 2024, the result of our deferring payment on certain payables as a result of our cash preservation strategy.

Historical Cash Flows

The following table summarizes our cash flows for the periods indicated:

  Three months ended      March 31,    (In thousands) 2025  2024  Change Cash Flows used in operating activities $(1,597) $(2,942) $1,345 Cash Flows provided by investing activities  -   1,269   (1,269)Cash Flows provided by financing activities  -   55   (55)Effect of exchange rate changes on cash  5   (2)  7 Net change in cash and cash equivalent during period $(1,592) $(1,620) $28 

Cash Flows from Operating Activities

During the three months ended March 31, 2025, cash used in operating activities was $1.6 million compared to $2.9 million during the three months ended March 31, 2024. Cash used in operating activities during the three months ended March 31, 2025, was attributed to a net loss of $2.4 million offset by decreases in operating assets and liabilities of $0.6 million and non-cash stock-based compensation of $0.2 million. Cash used in operating activities during the three months ended March 31, 2024, was attributed to a net loss of $2.5 million and a non-cash gain of $0.1 million associated with our trading of market